117 related articles for article (PubMed ID: 843258)
1. Juvenile parkinsonism treated with levodopa.
Sachdev KK; Singh N; Krishnamoorthy MS
Arch Neurol; 1977 Apr; 34(4):244-5. PubMed ID: 843258
[TBL] [Abstract][Full Text] [Related]
2. CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders.
Davidson DL; Yates CM; Mawdsley C; Pullar IA; Wilson H
J Neurol Neurosurg Psychiatry; 1977 Dec; 40(12):1136-41. PubMed ID: 591981
[TBL] [Abstract][Full Text] [Related]
3. Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.
Campanella G; Algeri S; Cerletti C; Dolfini E; Jori A; Rinaldi F
Eur J Clin Pharmacol; 1977 Apr; 11(4):255-61. PubMed ID: 862646
[No Abstract] [Full Text] [Related]
4. Brain dopamine turnover and the relief of parkinsonism.
Rinne UK; Sonninen V; Marttila R
Adv Exp Med Biol; 1977; 90():267-75. PubMed ID: 930747
[TBL] [Abstract][Full Text] [Related]
5. The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPG, HIAA and HVA levels in the cerebrospinal fluid.
Przuntek H; Kuhn W; Kraus P
Acta Neurol Scand Suppl; 1989; 126():153-6. PubMed ID: 2482649
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid homovanillic acid levels in rapid-onset dystonia-parkinsonism.
Brashear A; Butler IJ; Hyland K; Farlow MR; Dobyns WB
Ann Neurol; 1998 Apr; 43(4):521-6. PubMed ID: 9546335
[TBL] [Abstract][Full Text] [Related]
7. [Pathomechanism of dyskinesia associated with treatment of Parkinson disease with levodopa].
Friedman A
Neurol Neurochir Pol; 1981; 15(4):407-9. PubMed ID: 6173792
[TBL] [Abstract][Full Text] [Related]
8. [Drug-induced dyskinesia during the treatment of Parkinson disease--biochemical studies].
Friedman A
Neurol Neurochir Pol; 1985; 19(5):401-3. PubMed ID: 2421191
[TBL] [Abstract][Full Text] [Related]
9. Tetrahydrobiopterin and Parkinson's disease.
Dissing IC; Güttler F; Pakkenberg H; Lou H; Gerdes AM; Lykkelund C; Rasmussen V
Acta Neurol Scand; 1989 Jun; 79(6):493-9. PubMed ID: 2476906
[TBL] [Abstract][Full Text] [Related]
10. Unresponsiveness to L-DOPA in parkinsonian patients: a study of homovanillic acid concentration in the cerebrospinal fluid.
Nishi K; Kondo T; Narabayashi H; Takubo H; Muramoto S; Araki H
J Neurol Sci; 1989 Aug; 92(1):65-70. PubMed ID: 2475587
[TBL] [Abstract][Full Text] [Related]
11. Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for L-Dopa therapy.
Korf J; van Praag HM; Schut D; Nienhuis RJ; Lakke JP
Eur Neurol; 1974; 12(5-6):340-50. PubMed ID: 4448192
[No Abstract] [Full Text] [Related]
12. Juvenile parkinsonism: a patient with possible primary striatal dysfunction.
Naidu S; Wolfson LI; Sharpless NS
Ann Neurol; 1978 May; 3(5):453-5. PubMed ID: 727726
[TBL] [Abstract][Full Text] [Related]
13. Hereditary Parkinsonism-dystonia with sustained control by L-DOPA and anticholinergic medication.
Allen N; Knopp W
Adv Neurol; 1976; 14():201-13. PubMed ID: 942621
[No Abstract] [Full Text] [Related]
14. The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPS, HIAA, and HVA levels of cerebrospinal fluid.
Przuntek H; Kuhn W
Adv Neurol; 1990; 53():445-9. PubMed ID: 1700583
[No Abstract] [Full Text] [Related]
15. Homovanillic acid and 5-hydroxyindole-acetic acid in the csf of patients after a severe head injury. I. Lumbar csf concentration in chronic brain post-traumatic syndromes.
Bareggi SR; Porta M; Selenati A; Assael BM; Calderini G; Collice M; Rossanda M; Morselli PL
Eur Neurol; 1975; 13(6):528-44. PubMed ID: 1193100
[TBL] [Abstract][Full Text] [Related]
16. Ventricular fluid homovanillic acid and 5-hydroxyindoleacetic acid concentrations in patients with movement disorders.
Tabaddor K; Wolfson LI; Sharpless NS
Neurology; 1978 Dec; 28(12):1249-53. PubMed ID: 569783
[TBL] [Abstract][Full Text] [Related]
17. Failure of cerebrospinal fluid homovanillic acid to predict levodopa response in Parkinson's disease.
Weiner WJ; Klawans HL
J Neurol Neurosurg Psychiatry; 1973 Oct; 36(5):747-52. PubMed ID: 4753871
[TBL] [Abstract][Full Text] [Related]
18. Analysis of neurotransmitter metabolite concentrations in canine cerebrospinal fluid.
Vaughn DM; Coleman E; Simpson ST; Satjawatcharaphong C
Am J Vet Res; 1988 Aug; 49(8):1302-6. PubMed ID: 2459997
[TBL] [Abstract][Full Text] [Related]
19. Brain dopamine receptor stimulation and the relief of Parkinsonism: relationship between bromocriptine and levodopa.
Rinne UK; Marttila R
Ann Neurol; 1978 Sep; 4(3):263-7. PubMed ID: 718139
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism.
Rinne UK; Sonninen V; Marttila R
Adv Neurol; 1975; 9():383-92. PubMed ID: 1096575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
